FDA label 1f6e9772-889a-49b7-9c8a-7a29ed4b68fa

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
b2a9f856-3ef7-8da4-920c-f738e4f1f7d7
SPL ID
1f6e9772-889a-49b7-9c8a-7a29ed4b68fa
Version
31
Effective date
2025-08-21
Source export date
2026-11-13
Source partition
14
Source file
https://download.open.fda.gov/drug/label/drug-label-0014-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/087e7a9c7af51c6b12a0e8fd611a27cb8635e1910ad160b89995da9a4b39b1b3/drug-label-0014-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 18:18:22

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis, are possible. Should symptoms occur, discontinue THROMBATE III infusion and begin appropriate treatment. ( 5.1 ) Because THROMBATE III is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.2 ) Perform coagulation tests to avoid excessive or insufficient anticoagulation and monitor for bleeding or thrombosis. Measure functional plasma AT levels with amidolytic or clotting assays; do not use immunoassays. ( 5.3 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, may occur with THROMBATE III infusion. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include angioedema, chest tightness, hypotension, rash, nausea, vomiting, paresthesia, restlessness, wheezing and dyspnea. If hypersensitivity symptoms occur, discontinue use of the product immediately and administer appropriate emergency treatment. 5.2 Transmission of Infectious Agents Because THROMBATE III is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product. The risk that the product will transmit viruses has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and removing certain viruses during manufacture. Despite these measures, this product may still potentially transmit diseases. Report all infections suspected by a physician possibly to have been transmitted by this product to Grifols Therapeutics LLC at 1-800-520-2807. 5.3 Monitoring: Laboratory Tests The effect of drugs that use antithrombin to exert their anticoagulation may be altered when THROMBATE III is added or withdrawn. Regularly perform coagulation tests suitable for the anticoagulant used (e.g., aPTT and anti-Factor Xa activity) to avoid excessive or insufficient anticoagulation. Additionally, monitor the patients for the occurrence of bleeding or thrombosis. [see Drug Interactions (7) ] Measure functional levels of AT in plasma by amidolytic assays using chromogenic substrates or by clotting assays. Do not use immunoassays because they do not detect all hereditary AT deficiencies.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions (≥ 5% of patients) were dizziness, chest discomfort, nausea, dysgeusia, and pain (cramps). ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Grifols Therapeutics LLC at 1-800-520-2807 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in other clinical trials of another drug and may not reflect the rates observed in clinical practice. Two clinical trials were conducted in 33 patients with congenital AT deficiency. The first was a prospective, open-label, dose-escalation, dose-ranging, and pharmacokinetic study in 11 asymptomatic patients. Eight patients received a single dose, escalated sequentially, followed by weekly dose ranging from 25 to 125 unit/kg. Five patients (including 2 from the first part of the study) received weekly THROMBATE III for periods of up to 23 weeks in doses ranging from 125 to 225 unit/kg. The second trial was a phase III, prospective, open-label study conducted in 24 patients for additional kinetics (n=3), the prevention of thrombosis (n=13) during high risk conditions (pregnancy, surgery), or the treatment of thrombosis (n=10). Loading doses targeted an AT plasma level of 120% and ranged from 33 to 150 unit/kg. Maintenance doses targeted a plasma AT range of 70% to 120%, which were 23 to 75 unit/kg. Adverse reactions reported during the 2 clinical trials are listed in Table 2 . Nine patients (27%) experienced 29 adverse reactions which occurred during 17 of 389 infusions. There were no serious adverse reactions reported. The severity of adverse reactions was reported as mild or moderate, except for wound secretion and hematoma, which was severe. Table 2: Adverse Reactions Occurring during Hereditary Deficiency Trials Adverse Reaction By Patients N (%) (N=33 Patients) By Infusions N (%) (N=389 Infusions) Any adverse reaction 9 (27) 29 (7.5) Dizziness 4 (12) 8 (2.1) Chest discomfort 3 (9) 3 (0.8) Nausea 3 (9) 3 (0.8) Dysgeusia 2 (6) 3 (0.8) Pain (cramps) 2 (6) 2 (0.5) Chills 1 (3) 2 (0.5) Wound secretion and hematoma 1 (3) 2 (0.5) Vision blurred 1 (3) 1 (0.3) Chest pain 1 (3) 1 (0.3) Dyspnea 1 (3) 1 (0.3) Intestinal dilatation 1 (3) 1 (0.3) Pyrexia 1 (3) 1 (0.3) Urticaria 1 (3) 1 (0.3) During clinical investigation of THROMBATE III, there were no reports of virus transmission. None of 12 patients monitored for a median of 8 months (range 2–19 months) after receiving THROMBATE III became antibody positive to human immunodeficiency virus (HIV-1). None of 14 patients monitored for ≥ 3 months demonstrated any evidence of hepatitis.

adverse reactions table

<table ID="SPLSERV-8cc2e199-d88d-4d3d-aa16-d63c8a98032c" cellpadding="4" cellspacing="0" styleCode="Noautorules Botrule" width="60%"><caption>Table 2: Adverse Reactions Occurring during Hereditary Deficiency Trials</caption><colgroup><col/><col/><col/></colgroup><tbody><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule">Adverse Reaction</td><td align="center" styleCode="Botrule Lrule Rrule Toprule">By Patients N (%) (N=33 Patients)</td><td align="center" styleCode="Botrule Lrule Rrule Toprule">By Infusions N (%) (N=389 Infusions)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Any adverse reaction </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 9 (27) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 29 (7.5) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Dizziness </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 4 (12) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 8 (2.1) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Chest discomfort </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 3 (9) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 3 (0.8) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Nausea </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 3 (9) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 3 (0.8) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Dysgeusia </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 2 (6) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 3 (0.8) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Pain (cramps) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 2 (6) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 2 (0.5) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Chills </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (3) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 2 (0.5) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Wound secretion and hematoma </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (3) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 2 (0.5) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Vision blurred </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (3) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (0.3) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Chest pain </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (3) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (0.3) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Dyspnea </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (3) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (0.3) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Intestinal dilatation </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (3) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (0.3) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Pyrexia </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (3) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (0.3) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Urticaria </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (3) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> 1 (0.3) </td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.